Drugs / enhanced DefenAge 8-in-1 BioSerum
enhanced DefenAge 8-in-1 BioSerum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05082766 | Oct 2021 → Oct 2022 | — | Goldman, Butterwick, Fitzpatrick and Groff | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enhanced DefenAge 8-in-1 BioSerum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05082766 ↗ |
| Known as | DefenAge | “DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.” NCT05082766 ↗ |
| Known as | enhanced 8-in-1 BioSerum | “The primary objective of this study is to evaluate the efficacy of DefenAge 8-in-1 BioSerum supplemented with the enhanced concentration of defensins (enhanced 8-in-1 BioSerum)...” NCT05082766 ↗ |
| Route | Topical | “DefenAge is a topical skincare brand” NCT05082766 ↗ |